David A. Rider

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants.

A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants.

Journal: Journal of atherosclerosis and thrombosis

Published: May 10, 2026

Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.

Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.

Journal: JAMA

Published: November 18, 2024

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial.

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial.

Journal: JAMA

Published: April 08, 2024

Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease.

Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease.

Journal: Toxicological sciences : an official journal of the Society of Toxicology

Published: June 23, 2022

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.

Journal: Atherosclerosis

Published: October 30, 2021

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.

Journal: Cardiovascular research

Published: July 01, 2020

Central IRAK-4 kinase inhibition for the treatment of pain following nerve injury in rats.

Central IRAK-4 kinase inhibition for the treatment of pain following nerve injury in rats.

Journal: Brain, behavior, and immunity

Published: February 21, 2020

FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis.

FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis.

Journal: JCI insight

Published: November 02, 2018

Haplosaurus computes protein haplotypes for use in precision drug design.

Haplosaurus computes protein haplotypes for use in precision drug design.

Journal: Nature communications

Published: November 29, 2017

Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.

Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.

Journal: mAbs

Published: December 09, 2014

Does oxidative inactivation of CD45 phosphatase in rheumatoid arthritis underlie immune hyporesponsiveness?

Does oxidative inactivation of CD45 phosphatase in rheumatoid arthritis underlie immune hyporesponsiveness?

Journal: Antioxidants & redox signaling

Published: June 14, 2013

Differential expression of CD148 on leukocyte subsets in inflammatory arthritis.

Differential expression of CD148 on leukocyte subsets in inflammatory arthritis.

Journal: Arthritis research & therapy

Published: January 15, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026